Mein Warenkorb

Complement C5a

Complement C5a Molekülinformation

Englischer NameComplement C5aAnzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel2Target-AliasC5a Complement,Complement 5a,Complement Component 5a
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameComplement C5a
Target-AliasC5a Complement,Complement 5a,Complement Component 5a
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphaseApproved

Complement C5a Produktliste

  • Attribut

    Protein (6)Kits (2)

  • Produktbibliothek

    Online (8)

  • Spezies

    Human (4)Mouse (2)Cynomolgus (2)

  • Etikett

    Tag Free (2)His Tag (3)Fc Tag (1)- (2)

  • Marker

    Unconjugated (6)- (2)

Complement C5a Molekülhintergrund

Complement component C5a (C5a) is a protein fragment generated upon cleavage of complement component C5. It is a potent chemotactic factor for human peripheral blood neutrophils and monocytes and is believed to play an important role in a number of inflammatory conditions. The major functions of C5a are as follows: C5a is an anaphylatoxin, causing the release of histamine from mast cells; C5a is an effective leukocyte chemoattractant, promoting the accumulation of white blood cells, especially neutrophil granulocytes, at sites of complement activation; C5a activates white blood cells by increasing integrin avidity and upregulating the lipoxygenase pathway for arachidonic acid metabolism; C5a is a powerful inflammatory mediator and appears to be a key factor in the pathogenesis of many inflammatory diseases involving the complement system; and C5a modulates the balance between activating and inhibitory IgG Fc receptors on leukocytes, a mechanism that may enhance autoimmune responses under pathological conditions.

Complement C5a Molekülalias

C5a,Complement Component 5a

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
BDB-001BDB-001; BDB001; BDB 001; BDB-1Phase 3 ClinicalStaidson(Beijing) Biopharmaceuticals Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Hidradenitis Suppurativa; Vasculitis
Details
STSA-1002STSA-1002; STSA1002Phase 3 ClinicalStaidson(Beijing) Biopharmaceuticals Co LtdAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Coronavirus Disease 2019 (COVID-19); Respiratory Distress Syndrome, Adult
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
VilobelimabIFX-1; CaCP-29ApprovedInflarx NvGohibicEURespiratory Distress Syndrome, AdultInflarx Nv, Inflarx Gmbh2025-01-13Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Carcinoma, Squamous Cell; Coronavirus Disease 2019 (COVID-19); Drug-Related Side Effects and Adverse Reactions; Granulomatosis with Polyangiitis; Hidradenitis Suppurativa; Microscopic Polyangiitis; Pyoderma Gangrenosum; Respiratory Distress Syndrome, Adult; Sepsis; Shock, Septic; Systemic Inflammatory Response Syndrome
Details

Produktrezensionen

  • 1***52019-09-26
    0Menschen mögen
    I have ordered a lot of proteins from Acro. This one especially impressed me. Not only that they generously sent me the trial for my pre-experiment, but also they would develop different species of proteins that I need, which saved me a lot of time. Most importantly, ACRO not only does binding experiments, but also tests related functional assay. They even share them with customers. It is quite comprehensive. May all proteins come from you, ACRO.
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Produktrezensionen
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns